Across TCGA pan-cancer cohorts, EFHC1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EFHC1 data layer compared with 25 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher EFHC1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EFHC1 expression acts as an unfavorable survival marker.
LSCC and UCEC are the cancer types where EFHC1 mass-spec protein most reproducibly stratifies survival.